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Objectives: Second primary lung cancers are prevalent after treatment for 
initial lung cancer, and the lung is also one of the most frequent sites for 
recurrence after removal of early-stage lung cancer. The objective of the 
present study is to clarify the clonal origin of the second tumor with the p53 
gene mutation used as a clonal marker. Methods: Of 794 consecutive 
patients who underwent pulmonary resection for primary lung cancer from 
1980 to 1993, 22 required second pulmonary resection during the follow-up 
period, with a median interval of 38 months. We examined 16 of these 
patients for mutations of the p53 gene occurring in exons 5 through 8 by the 
polymerase chain reaction/single strand conformation polymorphism 
method. Differential diagnosis was also made on a morphologic basis, 
considering the degree of cellular differentiation and cytologic subtypes. 
Results: Nine of the 16 patients analyzed had at least one p53 mutation in 
their tumors. We were thus able to make molecular diagnoses for these 
patients. The mutational status of the p53 gene was discordant in all nine 
patients, suggesting a different clonal origin despite the fact that six of them 
had almost identical histologic features. Conclusions: Analysis of p53 gene 
mutations was thus useful in distinguishing second primary lung cancers 
from recurrent tumors. The observed heterogeneity of p53 status was also 
in line with the "field cancerization" concept. (J Thorac Cardiovasc Surg 
1997;114:354-60) 
T he incidence of lung cancer occurring as a second neoplasm is high after curative pulmonary resec- 
tion for early-stage lung cancer. For example, Pai- 
rolero, 1 Martini, 2 and their associates reported 10% 
and 12% incidences of second primary lung cancers, 
respectively, in their groups of 346 and 598 patients 
with resected stage I non-small-cell ung cancers. 1'2 
On the other hand, the lung, like the brain, is a 
frequent site of hematogenous recurrence after po- 
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tentially curative resection of lung cancer. 2-5 Conse- 
quently, it is sometimes difficult to distinguish mul- 
tiple primary tumors from recurrent umors. The 
fact that the histologic features of a second primary 
lung cancer tend to repeat hose of the initial lesion 
further compounds this problem. 6-s 
Martini and Melamed 6 in 1975 proposed the 
criteria that are currently most widely used for 
distinguishing multiple primary tumors from recur- 
rent tumors. Essentially, a second tumor is consid- 
ered as an independent primary tumor when the 
histologic haracteristics are different, or even when 
the histologic features are the same, if the free 
interval was more than 2 years or if the first tumor 
was resected at a relatively early stage. However, no 
definite theoretically sound background for these 
criteria has been established. 
Several major genetic approaches for determina- 
tion of the clonality of human tumors are based on 
X-chromosome inactivation analysis in female pa- 
tients, immunoglobulin or T-cell receptor gene anal- 
ysis for lymphoid tumors, and the occurrence of 
somatic mutations of oncogenes or tumor suppres- 
sor genes? Analysis of mutations occurring in the 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 3 
Mitsudomi et al. 3 5 5 
p53 tumor suppressor genes is considered particu- 
larly useful. With regard to lung cancers, the p53 
tumor suppressor gene has been found so far to be 
the most frequently mutated gene, with mutations 
present in 50% of non-small-cell and in almost all 
small-cell lung cancers. 1° The majority of mutations 
are widely' distributed, involving various codons in 
exons 5 through 8,1143 in clear contrast to the 
exclusive occurrence of ras gene mutations at 
codons 12., 13, or 61.14 Therefore it is not likely that 
two independent tumors would have the same p53 
mutation by chance alone. Another advantage is 
that mutations of the p53 gene occur relatively early 
in the development of lung cancer, especially in 
those of squamous cell type, 15 and because they 
have a role in maintenance of the malignant pheno- 
type, 16 once acquired they are well preserved uring 
progression or metastatic spread. 17 
In this study, we therefore xamined 16 patients 
with metachronous lung tumors to determine the 
applicability of p53 gene mutations for differentia- 
tion of second primary tumors in the lung. The 
molecular diagnostic results were also compared 
with diagnoses made on the morphologic features 
and with the clinical criteria proposed by Martini 
and Melamed. 6
Patients and methods 
Patients. During a M-year-period from 1980 to 1993, 
794 patients with primary lung cancers underwent pulmo- 
nary resection at the Department of Thoracic Surgery, 
Aichi Cancer Center Hospital. Of these, 22 (3%) required 
a second pulmonary resection by the end of 1995 for 
suspected second primary or solitary pulmonary recurrent 
tumors. In the present study, we analyzed 16 of these 
patients (32 tumors) for whom archival materials were 
available. The patients included 10 men and six women. 
Their median age at the time of the first operation was 55 
years (range 39 to 77 years). The histologic features of the 
two tumors were the same in 12 patients and different in 
the remaining four. The median interval between the two 
operations was 38 months (range 7 to 89 months). Fol- 
lowing the American Joint Committee staging system 
published in 1986, is 14 tumors at the first operation were 
classified as stage I and the remaining two were classified 
as stage II. 
Morphologic diagnosis of lung cancer. The resected 
tumors were routinely fixed in 10% formaldehyde and 
embedded in paraffin. Sections cut at 3 fLm were stained 
with hematoxylin and eosin for histologic examination. 
Differential diagnosis was based on the degree of cellular 
differentiation and the cytologic subtypes in the adenocar- 
cinoma cases, essentially as proposed by Shimosato. 19We 
combined the Clara cell subtype with the type II pneumo- 
cyte subtype to give a single group, referred to as adeno- 
carcinomas with peripheral airway cell morphology (PAC), 
because of the frequent coexistence of the two cell types. 
Consequently, adenocarcinomas were subclassified into 
PAC, bronchial surface epithelial cell (BrS), bronchial 
gland (BrG), goblet cell (Gob), and poorly differentiated 
(P/D) adenocarcinoma c tegories. For comparison with 
the World Health Organization classification, the PAC 
includes most bronchioloalveolar carcinomas and a large 
proportion of papillary adenocarcinomas, BrG includes 
the majority of acinar adenocarcinomas, BrSencompasses 
the remainder of the papillary and acinar adenocarcino- 
mas, and Gob constitutes a subcategory of bronchioloal- 
veolar carcinomas. 2° The second tumor was diagnosed as 
a second primary when the histologic type or cytologic 
subtype was different from that of the first lesion. 
Extraction of deoxyribonucleic acid from formalin- 
fixed paratiin.embedded materials. Single 8 /~m thick 
paraffin sections were used for genomic deoxyribonucleic 
acid (DNA) extraction. After deparaffinization with xy- 
lene, they were lightly stained with hematoxylin, and 
tumor cells were then microdissected out by means of a 
needle with a syringe under a dissecting microscope. The 
dissected tissue was digested in 50/xl of buffer consisting 
of tromethamine, 20 mmol/L (pH 8.0), ethylenediami- 
netetraacetic a id, 1 retool/L, 0.5% Tween 20, and protein- 
ase K, 200 /xg/ml, for 24 to 48 hours at 37°C and then 
incubated for 15 minutes at 95 ° C to inactivate the pro- 
teinase K, essentially as described by Sugio and cowork- 
ers. 2a Solution in aliquots of 1 /xl was used for each 
experiment. 
Polymerase chain reaction/single strand conformation 
polymorphism analysis. Mutations of the p53 gene occur- 
ring in exons 5 through 8 were screened by polymerase 
chain reaction/single strand conformation polymorphism 
(PCR/SSCP) analysis. 22 However, because of the limited 
quality of DNA extracted from formalin-fixed specimens, 
a hemi-nested PCR strategy was used to give PCR prod- 
ucts sized less than 200 base pairs. Exons 5 and 8 were 
each divided into two overlapping fragments. Sequences 
for the primers applied are available on request. One- 
microliter aliquots of the first PCR products were ream- 
plified with a pair of external primers in a volume of 10/xl 
including 0.5 /xl of [c~-32p]deoxycytidine triphosphate 
(3000 Ci/mmol, 10 mCi/ml, Amersham, Arlington, Ill.). 
The PCR products were diluted with loading buffer, heat 
degenerated, loaded onto nondenaturing 6% polyacryl- 
amide gels, and electrophoresed at 25 W for 5 hours or at 
40 W for 2.5 hours in a cold room (4 ° C) with or without 
a cooling fan, essentially as described elsewhere. 11After 
electrophoresis, the gels were dried and exposed to x-ray 
films at -70 ° C. 
Results 
Clinical diagnosis using Martini and Melamed's 
criteria and morphologic diagnosis considering cy- 
tologic subtypes. Following the criteria proposed by 
Martini and Melamed, 6 which are currently the most 
widely used for distinguishing multiple primary tu- 
mors from recurrent umors, multiple primary tu- 
mors were diagnosed in all 16 patients (Table I, 
column 4). 
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Table I. Patient characteristics and summary of  the results 
Histologic subtype/" p53 mutation 
Interval Clinical Morphologic Molecular 
Case Age, sex (mo) diagnosis* First tumor Second tumor diagnosis? First tumor Second tumor diagnosis 
1 56, M 8 M AD PAC AD P/D M - -  Ex 5 M§ 
2 62, F 37 M AD PAC AD PAC R - -  - -  ? 
3 71, M 73 M LA AD P/D M - -  - -  ? 
4 77, F 39 M AD PAC AD PAC R Ex 6 - -  M 
5 50, M 30 M SQ W/D AD BrG M Ex 6 Ex 8 M 
6 49, M 14 M AD BrS AD BrS R - -  - -  ? 
7 53, F 89 M AD PAC AD PAC R Ex 6 - -  M 
8 43, F 26 M AD PAC AD PAC R - -  - -  ? 
9 40, F 44 M AD BrS AD BrS R - -  - -  ? 
10 40, M 32 M AD P/D SQ M/D M - -  - -  ? 
11 57, M 43 M SQ M/D SQ M/D R - -  Ex 6 M§ 
12 58, F 57 M AD Gob AD Gob R - -  - -  ? 
13 53, M 7 M AD BrG AD BrG R Ex 7 - -  M 
14 39, M 44 M AD PAC AD PAC R - -  Ex 6 M§ 
15 58, M 66 M SQ M/D AD BrS M Ex 5 Ex 5~ M 
16 62, M 19 M SQ W/D SQ W/D R Ex 5, 8 Ex 5~ M 
AD, Adenocarcinoma; PAC, peripheral irway cell type; P/D, poorly differentiated; LA, large cell carcinoma; SQ, squamous cell carcinoma; W/D, well 
differentiated; BrG, bronchial g and type; BrS, bronchial surface type; M/D, moderately differentiated; Gob, goblet cell type; M, multiple primary lung cancer; 
R, recurrent metastatic umor; Ex, exon. 
*Clinical diagnosis according toMartini and Melamed. 6 
tMorphologic diagnosis was made using subclassification of adeuocarcinomas proposed by Shimosato. 19 
~Different p53 mutation from that in the corresponding first umor. 
§In these three cases, there was also a possibility hat he second tumor is a clonal expansion fthe first one (see text). 
The histologic combinat ions of the first and the 
second tumors in the 16 patients were adenocarci -  
noma-adenocarc inoma (n = 10, 63%), squamous 
carc inoma-adenocarc inoma (n = 2, 13%), squa- 
mous carc inoma-squamous carc inoma (n = 2, 
13%), adenocarc inoma-squamous  carc inoma (n = 
1, 6%), and large-cell  carc inoma-adenocarc inoma 
(n = 1, 6%). Hence, in 12 of 16 patients (75%), the 
histologic type of the second tumor was the same as 
that of the first. The incidence of adenocarc inomas 
in these mult iple cases (24 of 32 tumors, 75%) was 
higher than that for single lung cancers in our 
institution (52%). 
Consider ing the cytologic features of the adeno- 
carc inoma cells, 11 tumors were subclassified as 
PAC, five as BrS, three as BrG, two as Gob, and 
three as P/D. On the basis of  these histopathologic 
and cytopathologic results, mult iple pr imary tumors 
were diagnosed in one pat ient (case 1), in addit ion 
to the four patients for whom the major  histologic 
type of each tumor  differed. For  the remaining 11 
patients, the pairs of tumors belonged to the same 
morphologic  subset even when cytologic subtyping 
was considered, and they were thus diagnosed as 
recurrences (morphologic diagnosis) (Table I, col- 
umns 5 and 6, and Fig. 1, A, B, D, and E).  
Detection of p53 gene mutations and molecular 
diagnosis of clonality. SSCP analysis al lowed us to 
per form p53 gene analyses within 24 hours once 
DNA was extracted. Thirteen p53 gene mutat ions 
were detected in 12 tumors. The incidence was 12 of 
32 (38%) in total, five of seven (71%) in squamous 
cell carcinomas, and seven of 24 (29%) in adenocar-  
cinomas. None of the patients had the same p53 
mutat ions in their pairs of tumors. Fig. 1, C and F 
shows representat ive r sults. 
In seven patients neither tumor  harbored a p53 
mutation. In three patients, the first tumor  was 
negative for p53 mutat ion but the second one had a 
p53 mutation, as in Fig. 1, C (cases 1, 11, and 14; 
pattern A).  In another three patients, the first tumor 
had p53 mutat ion and the second one had none, as 
in Fig. 1, F (cases 4, 7, and 13; pattern B). In the 
remaining three patients, both tumors had p53 
mutat ions but they differed from each other (cases 
5, 15, and 16; pattern C). These results are summa- 
rized in Fig. 2. 
Discussion 
Only a relatively small number  of studies have 
been conducted concerning molecular  clonal analy- 
sis of metachronous lung cancer. Noguchi, 23 YangY 
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Fig. 1. Examples of comparisons ofhistologic features and PCR/SSCP of the p53 gene. A 57-year-old man 
(patient 11) underwent right upper lobectomy for squamous cell carcinoma (A). Three years 7 months 
later, a second squamous cell carcinoma (B) developed in the left upper lobe and was removed by 
lobectomy. PCR/SSCP analysis revealed amutation in exon 6 of the p53 gene in the second tumor but not 
in the first (C) (pattern A, see text), although the histologic features were almost identical. A 77-year-old 
woman (patient 4) underwent right middle lobectomy for an adenocarcinoma of peripheral irway cell type 
(139. Three years 3 months later, a second adenocarcinoma of the identical morphologic type (E) developed 
in the left lower lobe. PCR/SSCP analysis revealed amutation in the first tumor in exon 6 of the p53 gene, 
but this mutation was lost in the second lesion (F) (pattern B, see text). Arrows in panels C and F indicate 
the positions of bands for wild-type alleles. 
and their colleagues examined five and four pa- 
tients, respectively, among larger series of patients 
with head and neck tumors, but the present investi- 
gation, to our knowledge, is the first systematic 
molecular analysis of multiple primary lung cancers. 
The detected incidences of p53 gene mutations, 
five of seven (71%) for squamous cell carcinomas 
and seven of 24 (29%) for adenocarcinoma, re in 
good agreement with those reported previously for 
single lung cancers. 12' 13, 25 The fact that they were 
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metachronous lung tumors 
16 cases pattern A: 
3 cases  
pattern B: 
First tumor 
not informative 
7 cases mutation (-) 
3 cases 
pattern C: 
3 cases 
Second tumor 
mutation (-) 
mutation (-) W mutation (+) 
different clone or clonal expansion 
mutation (+) ~ mutation (-) 
different clone 
mutation (+) W mutation (+)* 
different clone 
* di f ferent mutat ion 
Fig. 2. Summary of p53 gene mutational status in metachronous l ng tumors in 16 cases. For explanation 
of patterns A to C, see text. 
distributed equally between the first and second 
lesions indicates that multiplicity itself is not associ- 
ated with the presence of p53 mutation. 
Nine of 16 patients (56%) had at least one p53 
mutation in their pairs of tumors. The mutational 
status of the p53 gene was discordant in all nine 
patients, despite the fact that six of them had almost 
identical histologic features. Because mutations of 
the p53 tumor suppressor gene are thought to 
confer a growth advantage, 26 it is not likely that they 
would be lost during progression or metastatic 
spread. In fact, Reichel and associates, 17 by exam- 
ining a total of 26 primary lung tumors and 60 
metastases, reported that the p53 mutational status 
was concordant in the primary tumor and its corre- 
sponding multiple metastases in 30 of 32 tumors 
(94%) that occurred in nine patients. Hence it can 
be concluded that the second tumor was different 
from the first in terms of clonal origin in three 
patients with pattern B (p53 mutation only in the 
first tumor) and in the other three patients with 
pattern C (different p53 mutation in the first and the 
second tumor). However, in three patients with 
pattern A (p53 mutation only in the second tumor), 
either of two conclusions are possible. One interpre- 
tation is that they are clonaUy different and the other 
is that the second tumor was in fact a clonal 
expansion, because of the growth advantage con- 
ferred by the p53 mutation in a minor clone that had 
been present in the first tumor but was not detected 
because of dilution effect, as has been shown in 
progression of astrocytoma. 26 The results of the 
molecular diagnosis made in accordance are sum- 
marized in the last column of Table I and in Fig. 2. 
It has been stated that, in treating metachronous 
lung cancer, the distinction between a new primary 
tumor and a solitary metastasis  of little impor- 
tance if the new tumor is resectable. 6 However, 
these observations are based on conventional crite- 
ria of second primary cancers. Hence a molecularly 
defined second primary tumor might behave differ- 
ently from a molecularly defined recurrent tumor. 
Consequently, it might be important to distinguish 
them at the time of diagnosis and to select appro- 
priate treatment. This is possible, inasmuch as we 27 
have previously shown feasibility of detection of p53 
mutation in a small bronchial biopsy specimen. 
However, whether treatment policy should depend 
on molecular diagnosis remains an issue for future 
investigation. 
The fact that the p53 mutational status was dis- 
cordant in our study supports the "field canceriza- 
tion" concept. 28 In other words, carcinogenic insults 
affect many different susceptible cells in the respira- 
tory tract, resulting in either synchronous or meta- 
chronous clonally distinct multiple tumors. Simi- 
larly, Noguchi and colleagues 23reported all seven 
p53 mutations found in four patients with metachro- 
nous lung tumors to be different. Chung and asso- 
ciates 29 examined 31 patients with primary head and 
neck tumors and corresponding second primary 
tumors of the upper aerodigestive tract and found 
21 to have at least one p53 mutation, again with 
discordance in terms of presence or location in all 
cases. Furthermore, with field cancerization, it
might be expected that a particular type of cell in the 
respiratory tract of a given patient (e.g., epithelial or 
nonepithelial) would preferentially commit to tu- 
morigenesis by carcinogen(s) exposure proper to the 
patient. Hence, in more than 70% of the cases, the 
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histologic type of the second tumor repeats that of 
the first. 6' 8 This was also true for the present series, 
even when subclassification of histologic type was 
considered, except in patient 1 (see Table I). How- 
ever, the p53 gene mutations would not necessarily 
occur in the same codon in a given combination of a 
carcinogen and a type of cells. This may at least 
partially account for the discrepancy between mo- 
lecular and morphologic diagnosis observed in the 
present study. 
All but two of the first tumors were classified as 
stage I, and median age of the patients at the time of 
the first operation was 55 years, which was appre- 
ciably younger than the age (62 years) of all patients 
who underwent pulmonary resection for lung cancer 
in our institution. These young patients with early- 
stage lung cancer have a good chance for cure of the 
first primary tumor and thus have a long time for 
development of a second primary lesion. Alterna- 
tively, these young patients may have been heavily 
exposed to carcinogen(s), lung cancer thus may have 
developed earlier, and the patients may have been at 
higher risk: for the development of a second primary 
tumor because of field effect of the carcinogen(s). 
Also, the possibility exists that genetic predisposi- 
tion, such as a defect in the DNA repair system, 3° 
could be playing a role. 
In addition to p53 gene mutations, several other 
molecular tools are currently available for analysis 
of the clonality of lung cancers. Analysis of X- 
chromosonaal inactivation occurring at early embry- 
onic development is attractive 9 but is applicable only 
to female patients. Loss of heterozygosity of certain 
chromosomal rms such as 3p, 5q, 9p, l lp, 13q, 17p, 
and 18q or mutations of ras genes are also possible. 
Although laborious, combining multiple genetic 
markers would certainly increase information con- 
cerning the clonal origin of tumors. 
In conclusion, the present examination of meta- 
chronous lung tumors for p53 gene mutations al- 
lowed clear diagnosis of multiple primary tumors in 
the majority of patients despite similarities in his- 
topathologic features. 
We are grateful to Hiroji Ishida, Miyoko Mabuchi, and 
Yoshiroh Tokoro for their expert technical assistance. 
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